Roche Kills Acmopatide, Bets on Enicepatide 22.5%

Roche (RHHBY) disclosed in its Q2 2026 earnings update on July 24 that it is discontinuing acmopatide (CT-868), a dual GLP-1/GIP receptor agonist from its $2.7 billion Carmot Therapeutics acquisition, despite the drug meeting its primary Phase 2 endpoint in type 1 diabetes with obesity. The company is prioritizing enicepatide (CT-388), the lead Carmot asset, which showed 22.5% placebo-adjusted weight loss in Phase 2 with no tolerability ceiling at the 24-mg dose and no weight-loss plateau at 48 weeks. RHHBY closed at $54.70 on July 24.

The discontinuation is a portfolio prioritization call, not an efficacy failure. Acmopatide reduced A1C by 0.34% from baseline and got 56% of patients to the under 7% A1C target. But Roche sees greater value in concentrating resources on enicepatide’s multi-indication potential across obesity, type 2 diabetes, and cardiovascular outcomes, where the addressable market is far larger.

What the data showed

Enicepatide is a dual GLP-1/GIP receptor agonist delivered as a once-weekly subcutaneous injection. In the Phase 2 trial (NCT06525935), patients titrated to the 24-mg dose achieved 22.5% placebo-adjusted weight loss without reaching a plateau at 48 weeks. That trajectory is unusual in GLP-1 trials, where weight loss typically flattens by week 36 to 48. A drug still climbing at that point suggests a deeper or more durable weight loss mechanism than first-generation incretin agonists.

Roche plans a broad Phase 3 program for enicepatide in obesity, type 2 diabetes, and cardiovascular outcomes, with a regulatory submission for obesity as early as 2028.

Why this matters

The obesity drug market is projected to exceed $100 billion by 2030. Roche’s enicepatide is emerging as a credible third entrant alongside Eli Lilly’s retatrutide (a triple-G agonist whose TRIUMPH-2/3 data was reported July 23) and Novo Nordisk’s semaglutide and cagrilintide franchises. The 22.5% weight loss approaches the 24 to 25% range Lilly’s retatrutide achieved, positioning enicepatide as a best-in-class efficacy candidate, though it trails Lilly by 1 to 2 years on filing timeline.

The Carmot acquisition was Roche’s $2.7 billion bet on obesity. Killing one of two lead assets 18 months in signals management is willing to make hard cuts to focus the portfolio. Three cancer drugs were also cut in the same R&D clearout, according to FierceBiotech.

What to watch next

Watch for Phase 3 trial design and timeline disclosure, which should come at a medical meeting or investor day in late 2026. The key risk is the 2028 filing timeline: Lilly and Novo are already in late-stage development with competing dual and triple agonists. If enicepatide’s Phase 3 starts a year late, it launches into a market where entrenched competitors hold formulary position and real-world evidence.

What It Means for the Trade

Killing acmopatide is being spun as prioritization, and it is — but be honest about the arithmetic. Roche paid $2.7 billion for Carmot’s portfolio and is now down to one lead obesity asset, 18 months in, with three cancer drugs cut in the same clearout. The concentrated bet on enicepatide is defensible: 22.5% placebo-adjusted weight loss with no plateau at 48 weeks and no tolerability ceiling at 24 mg is, on paper, the most differentiated dataset Roche owns. But concentration cuts both ways. If enicepatide’s Phase 3 disappoints, Roche exits the obesity market it spent $2.7 billion entering, and RHHBY at $54.70 gets no credit for having tried.

The 2028 filing timeline is the real constraint. Lilly’s retatrutide is a year to two ahead with 24-25% weight loss already in hand — a cross-trial comparison, but the direction is clear. Roche is not racing to be first; it is racing to be relevant at all.

Program Context

The acmopatide data itself was not the problem. A 0.34% A1C reduction and 56% of patients under 7% is a workable type 1 diabetes with obesity profile. Roche’s argument is that a type 1 niche cannot justify the Phase 3 spend when the same resources can push a 22.5%-weight-loss asset across obesity, type 2 diabetes, and cardiovascular outcomes in a market projected above $100 billion by 2030. That is correct capital logic. What it quietly concedes is that dual-agonist alone — GLP-1/GIP without a third axis — may no longer be enough to win. Lilly is running a triple-G, and if the market’s efficacy bar moves to 25%+, enicepatide’s 22.5% will have to defend on tolerability and, eventually, on Roche’s ability to pair it with anything oral.

The no-plateau-at-48-weeks detail deserves attention. Incretin curves typically flatten by week 36-48; a still-climbing trajectory at 48 weeks suggests durability that weekly semaglutide does not show, and durability is what drives chronic-therapy revenue, which is what the $100 billion projection actually assumes.

Risks and What Could Go Wrong

1. Phase 3 starts late. Every quarter of delay compounds the formulary and real-world-evidence gap against Lilly and Novo. Watch for concrete trial design disclosure in late 2026 — vagueness there is the tell.
2. Phase 2 does not replicate. Single-site-quality Phase 2 weight loss numbers have compressed at scale before.
3. The market moves. A 22.5% asset filing in 2028 may launch as a mid-tier efficacy product in a best-in-class market, with pricing to match. Roche needs enicepatide to be top-three on at least one axis that payers will pay for.

BioSpace coverage | FierceBiotech coverage